Publication | Open Access
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
89
Citations
30
References
2017
Year
Our data suggest that concomitant treatment with osimertinib and T-DM1 may be a promising therapeutic strategy for EGFR-mutant NSCLC.
| Year | Citations | |
|---|---|---|
Page 1
Page 1